User: Guest  Login
More Searchfields
Simple search
Title:

Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland.

Document type:
Journal Article
Author(s):
Schumann, Katharina; Mauch, Cornelia; Klespe, Kai-Christian; Loquai, Carmen; Nikfarjam, Ulrike; Schlaak, Max; Akçetin, Larissa; Kölblinger, Peter; Hoellwerth, Magdalena; Meissner, Markus; Mengi, Guelcin; Braun, Andreas Dominik; Mengoni, Miriam; Dummer, Reinhard; Mangana, Joanna; Sindrilaru, Mihaela-Anca; Radmann, Dan; Hafner, Christine; Freund, Johann; Rappersberger, Klemens; Weihsengruber, Felix; Meiss, Frank; Reinhardt, Lydia; Meier, Friedegund; Rainer, Barbara; Richtig, Erika; Ressler, Julia...     »
Abstract:
BACKGROUND: Programmed death-1 (PD-1) antibodies and BRAF + MEK inhibitors are widely used for adjuvant therapy of fully resected high-risk melanoma. Little is known about treatment efficacy outside of phase III trials. This real-world study reports on clinical outcomes of modern adjuvant melanoma treatment in specialized skin cancer centers in Germany, Austria and Switzerland. METHODS: Multicenter, retrospective study investigating stage III-IV melanoma patients receiving adjuvant nivolumab (NI...     »
Journal title abbreviation:
J Eur Acad Dermatol Venereol
Year:
2023
Journal volume:
37
Journal issue:
5
Pages contribution:
894-906
Fulltext / DOI:
doi:10.1111/jdv.18779
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/36433688
Print-ISSN:
0926-9959
TUM Institution:
1025; 1205; 600; Klinik und Poliklinik für Dermatologie und Allergologie
 BibTeX